Many investors pay attention to mid-cap stocks because they have established business models and expansive market ...

Despite record beef prices linked to a country-wide cattle shortage, long lines formed at butcher shops Tuesday. TMJ4 spoke with some in line to hear how the price hike is affecting their wallets.

Insulet Corporation (NASDAQ:PODD) is one of the best growth stocks to buy in 2026. On December 18, Truist lowered the firm’s ...

Insulet Corporation (NASDAQ:PODD) develops, manufactures, and sells insulin delivery systems for people with ...

In a report released on December 16, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Insulet, with a price target of $380.00. The company’s shares closed yesterday at $288.73.

Insulet announced amendments to its Annual Incentive Plan effective January 1, 2026, with revisions that impact terms regarding termination, retirement eligibility for prorated awards, compensation ...

Fintel reports that on November 19, 2025, UBS upgraded their outlook for Insulet (NasdaqGS:PODD) from Neutral to Buy. Analyst Price Forecast Suggests 9.42% Upside As of November 17, 2025, the average ...

Insulet Corp. closed 18.61% short of its 52-week high of $354.88, which the company achieved on November 20th.

(Photo by Kirk Mckoy/Los Angeles Times via Getty Images) When it comes to surgical innovation, Intuitive Surgical (NASDAQ: ISRG) often dominates investor attention. But Insulet Corporation (NASDAQ: ...

Below is Validea's guru fundamental report for INSULET CORP (PODD). Of the 22 guru strategies we follow, PODD rates highest using our Twin Momentum Investor model based on the published strategy of ...